Medicaid Expansion Tops Savings Versus Marketplace

This article originally appeared here.
Share this content:
Medicaid Expansion Tops Savings Versus Marketplace
Medicaid Expansion Tops Savings Versus Marketplace

MONDAY, Feb. 2, 2015 (HealthDay News) -- Medicaid expansion is associated with greater reductions in out-of-pocket spending for previously uninsured low-income adults than Marketplace exchange coverage with premium tax credits and generous benefits, according to a report published in the January issue of Health Affairs.

Steven C. Hill, Ph.D., from the Agency for Healthcare Research and Quality in Rockville, Md., compared the out-of-pocket spending for care and premiums for families of adults in two simulated scenarios: obtaining coverage through a Marketplace silver plan with subsidized cost sharing and enrolling in expanded Medicaid.

Hill notes that Medicaid would more than halve the average annual out-of-pocket spending compared with Marketplace coverage ($938 versus $1,948). Medicaid coverage would also reduce the percentage of adults in families with out-of-pocket expenses exceeding 10 percent of income (6.0 versus 17.1 percent) or 20 percent of income (0.9 versus 3.7 percent). For families with smokers, who under Medicaid would not be subject to Marketplace tobacco user surcharges, the reductions would be larger.

"Medicaid expansion may offer a greater opportunity than access to Marketplace insurance to promote the financial well-being of previously uninsured low-income adults," Hill writes.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »